Syndicate

Latest California Healthline Stories

Doctors Weigh Pros and Cons of Prescribing Hot-Button Alzheimer’s Drug

The potential benefits of Aduhelm are small, its effectiveness is not certain, and even the FDA Thursday shifted its guidance on who should get the drug. But physicians are dealing with an onslaught of interest from patients and their families, and figuring out which patients are best positioned to be helped by the drug will be difficult.

Drugmakers’ Spending on Stock, Dividends and Executive Pay Exceeds Research, Democrats Say

The pharmaceutical industry argues that large profits are needed to fund extensive research and innovation. But Democrats on the House Oversight and Reform Committee, seeking to bolster their effort to let Medicare negotiate drug prices, say major drug companies plow more of their billions in earnings back into propping up their stock and enriching executives and shareholders.

‘An Arm and a Leg’: Tips for Fighting Medical Bills from ProPublica’s Marshall Allen

Veteran health journalist Marshall Allen has been exposing health care grifters for years. Now he’s written a book about how to fight them. Host Dan Weissmann spoke with Allen about some of the best tips from “Never Pay the First Bill: And Other Ways to Fight the Health Care System and Win.”

Paying Billions for Controversial Alzheimer’s Drug? How About Funding This Instead?

Aduhelm, approved by the Food and Drug Administration last month despite questions about its efficacy, could be prescribed to at least 1 million patients a year, for a price tag of about $56 billion. Experts suggest there might be better ways to spend that money.